{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:43:10Z","timestamp":1794559390269,"version":"4.9.1"},"reference-count":38,"publisher":"FapUNIFESP (SciELO)","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"DOI":"10.1590\/1806-9282.67.02.20200521","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T12:27:22Z","timestamp":1629116842000},"page":"207-212","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of serum ghrelin, nesfatin-1, irisin, and vasoactive intestinal peptide levels in temporal lobe epilepsy patients with and without drug resistance: a cross-sectional study"],"prefix":"10.1590","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5275-6254","authenticated-orcid":false,"given":"Ozlem Ergul","family":"Erkec","sequence":"first","affiliation":[{"name":"Van Y\u00fcz\u00fcnc\u00fc Y\u0131l University,  Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2298-9596","authenticated-orcid":false,"given":"Aysel","family":"Milanl\u0131o\u011flu","sequence":"additional","affiliation":[{"name":"Van Y\u00fcz\u00fcnc\u00fc Y\u0131l University,  Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0371-9251","authenticated-orcid":false,"given":"Ahmet Ufuk","family":"Komuroglu","sequence":"additional","affiliation":[{"name":"Van Y\u00fcz\u00fcnc\u00fc Y\u0131l University,  Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8864-9706","authenticated-orcid":false,"given":"Mehmet","family":"Kara","sequence":"additional","affiliation":[{"name":"Van Y\u00fcz\u00fcnc\u00fc Y\u0131l University,  Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7623-1492","authenticated-orcid":false,"given":"Zubeyir","family":"Huyut","sequence":"additional","affiliation":[{"name":"Van Y\u00fcz\u00fcnc\u00fc Y\u0131l University,  Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0131dd\u0131k","family":"Keskin","sequence":"additional","affiliation":[{"name":"Van Y\u00fcz\u00fcnc\u00fc Y\u0131l University,  Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2021,2]]},"reference":[{"key":"ref1","series-title":"Epilepsy","year":"2019"},{"issue":"7","key":"ref2","first-page":"439","article-title":"Drug-resistant epilepsy: definition and treatment alternatives","volume":"30","author":"L\u00f3pez Gonz\u00e1lez FJ","year":"2015","journal-title":"Neurologia"},{"key":"ref3","series-title":"Molecular neurology","first-page":"600","author":"Waxman S","year":"2010"},{"issue":"9","key":"ref4","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jama.2012.220","article-title":"Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial","volume":"307","author":"Engel Jr J","year":"2012","journal-title":"JAMA"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/pr.120.019539","article-title":"Drug resistance in epilepsy: clinical \u0131mpact, potential mechanisms, and new \u0131nnovative treatment options","volume":"72","author":"L\u00f6scher W","year":"2020","journal-title":"Pharmacol Rev"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/epi.12191","article-title":"Pharmacoresistant epilepsy: unmet needs in solving the puzzle(s)","volume":"54","author":"Weaver DF","year":"2013","journal-title":"Epilepsia"},{"key":"ref7","series-title":"Ghrelin receptors and epilepsy","first-page":"177","author":"Portelli J","year":"2014"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.seizure.2017.07.014","article-title":"Novel therapeutic targets for epilepsy intervention","volume":"51","author":"Kambli L","year":"2017","journal-title":"Seizure"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2741\/709","article-title":"Pharmacoresistant epilepsy and nanotechnology","volume":"6","author":"Rosillo-de la Torre A","year":"2014","journal-title":"Front Biosci (Elite Ed)"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12035-014-8669-x","article-title":"Neuropeptides as targets for the development of anticonvulsant drugs","volume":"50","author":"Clynen E","year":"2014","journal-title":"Mol Neurobiol"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.npep.2013.10.015","article-title":"Neuropeptides in epilepsy","volume":"47","author":"Kovac S","year":"2013","journal-title":"Neuropeptides"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1528-1167.2012.03423.x","article-title":"Ghrelin: an emerging new anticonvulsant neuropeptide","volume":"53","author":"Portelli J","year":"2012","journal-title":"Epilepsia"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s13311-012-0125-x","article-title":"Inactivation of the constitutively active ghrelin receptor attenuates limbic seizure activity in rodents","volume":"9","author":"Portelli J","year":"2012","journal-title":"Neurotherapeutics"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/157015909787602779","article-title":"Ghrelin in central neurons","volume":"7","author":"Ferrini F","year":"2009","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.seizure.2005.11.008","article-title":"Serum ghrelin levels are enhanced in patients with epilepsy","volume":"15","author":"Berilgen MS","year":"2006","journal-title":"Seizure"},{"issue":"1-2","key":"ref16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11010-009-0073-x","article-title":"Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders","volume":"328","author":"Aydin S","year":"2009","journal-title":"Mol Cell Biochem"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.peptides.2011.04.021","article-title":"Time-dependent changes in the serum levels of prolactin, nesfatin-1 and ghrelin as a marker of epileptic attacks young male patients","volume":"32","author":"Aydin S","year":"2011","journal-title":"Peptides"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/01616412.2018.1503992","article-title":"Evaluation of ghrelin, nesfatin-1 and irisin levels of serum and brain after acute or chronic pentylenetetrazole administrations in rats using sodium valproate","volume":"40","author":"Erkec OE","year":"2018","journal-title":"Neurol Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/bonekey.2015.134","article-title":"Role of Irisin on the bone-muscle functional unit","volume":"4","author":"Colaianni G","year":"2015","journal-title":"Bonekey Rep"},{"issue":"8","key":"ref20","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s10072-018-3448-5","article-title":"Circulating irisin and chemerin levels as predictors of seizure control in children with idiopathic epilepsy","volume":"39","author":"Elhady M","year":"2018","journal-title":"Neurol Sci"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.npep.2011.12.002","article-title":"Nesfatin-1, a unique regulatory neuropeptide of the brain","volume":"46","author":"Pa\u0142asz A","year":"2012","journal-title":"Neuropeptides"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2174\/0929867320666131119154018","article-title":"Receptors of peptides as therapeutic targets in epilepsy research","volume":"21","author":"Dobolyi A","year":"2014","journal-title":"Curr Med Chem"},{"issue":"1","key":"ref23","first-page":"2","article-title":"Diagnosis and treatment of temporal lobe epilepsy","volume":"1","author":"Devinsky O","year":"2004","journal-title":"Rev Neurol Dis"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan P","year":"2010","journal-title":"Epilepsia"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies","volume":"12","author":"von Elm E","year":"2014","journal-title":"Int J Surg"},{"issue":"5","key":"ref26","article-title":"Effects of helicobacter pylori infections on ghrelin and leptin levels","volume":"32","author":"Kefeli A","year":"2016","journal-title":"Arch Sicil Med Chir 4 Acta Med Mediterr"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.peptides.2007.04.003","article-title":"Antiepileptic effects of ghrelin on pentylenetetrazole-induced seizures in rats","volume":"28","author":"Obay BD","year":"2007","journal-title":"Peptides"},{"issue":"Pt B","key":"ref28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.neuropharm.2017.12.027","article-title":"Ghrelin mediated neuroprotection \u2013 A possible therapy for Parkinson\u2019s disease?","volume":"136","author":"Morgan AH","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fnmol.2011.00023","article-title":"Neuroprotective actions of ghrelin and growth hormone secretagogues","volume":"4","author":"Frago LM","year":"2011","journal-title":"Front Mol Neurosci"},{"key":"ref30","series-title":"Neuropeptide receptors as potential antiepileptic drug targets: focus on the ghrelin axis","first-page":"3","volume":"2","author":"Portelli J","year":"2014"},{"key":"ref31","series-title":"Preclinical evidence of ghrelin as a therapeutic target in epilepsy","first-page":"59929","volume":"8","author":"Ge T","year":"2017"},{"issue":"2","key":"ref32","first-page":"265","article-title":"NPY receptors blockade prevents anticonvulsant action of ghrelin in the hippocampus of rat","volume":"3","author":"Ghahramanian Golzar M","year":"2013","journal-title":"Adv Pharm Bull"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.peptides.2012.04.014","article-title":"The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain","volume":"36","author":"Tang CH","year":"2012","journal-title":"Peptides"},{"issue":"8","key":"ref34","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1096\/fj.02-0799fje","article-title":"Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson\u2019s disease by blocking microglial activation","volume":"17","author":"Delgado M","year":"2003","journal-title":"FASEB J"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ana.410290316","article-title":"A selective loss of somatostatin in the hippocampus of patients with temporal-lobe epilepsy","volume":"29","author":"Robbins RJ","year":"1991","journal-title":"Ann Neurol"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1460-9568.1990.tb00385.x","article-title":"Neuropeptide Levels after Pentylenetetrazol Kindling in the Rat","volume":"2","author":"Marksteiner J","year":"1990","journal-title":"Eur J Neurosci"},{"issue":"8","key":"ref37","first-page":"391","article-title":"Somatostatin, substance P, prolactin and vasoactive intestinal peptide levels in serum and cerebrospinal fluid of children with seizure disorders","volume":"7","author":"Ko FJ","year":"1991","journal-title":"Gaoxiong Yi Xue Ke Xue Za Zhi"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.phrs.2018.01.012","article-title":"A glance at the therapeutic potential of irisin against diseases involving inflammation, oxidative stress, and apoptosis: An introductory review","volume":"129","author":"Askari H","year":"2018","journal-title":"Pharmacol Res"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v67n2\/1806-9282-ramb-67-02-0207.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T12:28:10Z","timestamp":1629116890000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302021000300207&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["S0104-42302021000300207"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.67.02.20200521","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"value":"1806-9282","type":"electronic"},{"value":"0104-4230","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}